Skip to main content
. 2022 Jan 17;54(1):211–226. doi: 10.1080/07853890.2021.2011956

Table 1.

Clinicopathological characteristics at surgery in relation to PTTG1 expression status in pRCC patients from FUSCC cohort.

Variable Entire group (n = 126) PTTG1 expression
χ 2 p-value
Low expression (n = 63) High expression (n = 63)
Age at surgery (y, median ± SD)   57.0 ± 11.7 57.0 ± 13.2    
BMI (kg/m2, median ± SD)   22.9 ± 3.4 22.5 ± 3.2    
Tumour size (cm, median ± SD)   4.0 ± 2.5 5.0 ± 3.0    
OS time (month, median ± SD)   54.0 ± 35.6 42.0 ± 35.2    
PFS time (month, median ± SD)   54.0 ± 38.7 36.0 ± 39.7    
Sex (n, %)       0.904 .342
 Male 85, 67.5% 45, 71.4% 40, 63.5%    
 Female 41, 32.5% 18, 28.6% 23, 36.5%    
Laterality (n, %)       1.581 .209
 Left 71, 56.3% 39, 61.9% 32, 50.8%    
 Right 55, 43.7% 24, 38.1% 31, 49.2%    
Tumour type       0.293 .588
 Type 1 pRCC 53, 42.1% 28, 44.4% 25, 39.7%    
 Type 2 pRCC 73, 57.9% 35, 55.6% 38, 60.3%    
T stage (n, %)       3.889 .049
 T1–T2 90, 71.4% 50, 79.4% 40, 63.5%    
 T3–T4 36, 28.6% 13, 20.6% 23, 36.5%    
N stage (n, %)       6.038 .014
 N0 101, 80.2% 56, 88.9% 45, 71.4%    
 N1 25, 19.8% 7, 11.1% 18, 28.6%    
M stage (n, %)       5.704 .017
 M0 99, 78.6% 55, 87.3% 44, 69.8%    
 M1 27, 21.4% 8, 12.7% 19, 30.2%    
AJCC stage (n, %)       7.327 .007
 I–II 73, 57.9% 44, 69.8% 29, 46.0%    
 III–IV 53, 42.1% 19, 30.2% 34, 54.0%    
Furhman grade (n, %)       7.966 .005
 1–2 27, 21.4% 20 , 31.7% 7, 11.1%    
 3–4 99, 78.6% 43, 68.3% 56, 88.9%    
ICB response (n = 62)   n = 19 n = 43 3.99 .046
 PD/SD 41, 66.1% 16, 84.2% 25, 58.1%    
 PR/CR 21, 33.9% 3, 15.8% 18, 41.9%    

pRCC: papillary renal cell carcinoma; FUSCC: Fudan University Shanghai Cancer Centre; BMI: body mass index; AJCC: American Joint Committee on Cancer; ICB: immune checkpoint blockade. *p-value less than .05 was considered as statistically significant and marked in bold.